Opinion|Videos|March 17, 2025
TAR-200 for Treatment of BCG-Unresponsive, High-Risk NMIBC
Author(s)Karim Chamie, MD, MSHS
An expert discusses how the SunRISe-1 phase 2b trial, presented at the European Society for Medical Oncology 2024 Congress (ESMO 2024), evaluated TAR-200 alone and with cetrelimab in BCG-unresponsive, high-risk non–muscle invasive bladder cancer (NMIBC). TAR-200 monotherapy achieved an 84% complete response rate, with most adverse events being mild to moderate. The combination therapy showed higher rates of severe adverse events. TAR-200 is particularly promising for patient’s ineligible for or refusing radical cystectomy.
Advertisement
Video content above is prompted by the following:
- The results of the SunRISe-1 phase 2b clinical trial, which investigated the use of the TAR-200 delivery system alone vs with cetrelimab, were recently presented at ESMO 2024.
- What are your impressions of the safety and efficacy data?
- Which patients might be the best candidates for the TAR-200 delivery system based on this data?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Annual ACS NCDB report details national trends in prostate cancer care
2
Pearls & Perspectives: Mindfulness, Performance, and Prostate Cancer Care, with Phillip M. Pierorazio, MD
3
Docetaxel plus tumor-targeting IL-12 yields promising activity in mCRPC
4
FDA provides guidance on development pathway for testosterone therapy for women
5